Special Drug Use-Results Survey of Lipitor Tablets
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 24,050
- 主要终点
- Changes in plasma LDL-C concentration
研究概览
简要总结
This study is to evaluate the controlling effect of atrovastatin on plasma lipid to achieve the category-specific targeted lipid levels.
详细描述
To confirm the low-density lipoprotein cholesterol (LDL-C)-lowering effect of 24 weeks of treatment with Lipitor®(Generic Name : atorvastatin calcium) Tablets and determine the rate of achievement of the category-specific target LDL-C level in patients with hypercholesterolemia; and to confirm the usefulness (efficacy and safety) of atorvastatin in patients who have not responded sufficiently to other statin therapies
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
atrovastatin group
Who receive atrovastatin
干预措施: atrovastatin (Drug)
结局指标
主要结局
Changes in plasma LDL-C concentration
时间窗: 0, 4, 12 and 24 week
Change in rate of achievement of the category-specific target LDL-C level
时间窗: 0, 4, 12 and 24 week
次要结局
- Changes in renal function test values (urinary albumin, urinary creatinine, urinary protein, and serum creatinine)(0, 4, 12 and 24 week)
- Change in plasma lipid values (LDL cholesterol, HDL cholesterol, triglycerides, total cholesterol, and malondialdehyde-modified LDL [MDL-LDL])(0, 4, 12 and 24 week)